NKGEN BIOTECH
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 63
- Market Cap
- -
- Website
- http://www.nkgenbiotech.com
- Introduction
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06189963
- Locations
- 🇺🇸
Behavioral Research Specialists, LLC, Glendale, California, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸Valiance Clinical Research, Tarzana, California, United States
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy
- Conditions
- Pathologically Confirmed Cancer Refractory to Conventional TherapySolid Tumor, AdultRefractory CancerRecurrent CancerAdvanced CancerMetastatic CancerSolid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05990920
- Locations
- 🇺🇸
Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
- Conditions
- Squamous Cell Carcinoma of Head and NeckCarcinoma, Non-Small-Cell LungColorectal NeoplasmsAdvanced Solid TumorRefractory TumorMetastatic Tumor
- Interventions
- Biological: SNK01
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05099549
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)
- Conditions
- Neuro-Degenerative DiseaseAlzheimer Disease
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- NKGen Biotech, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04678453
- Locations
- 🇲🇽
Hospital Angeles Tijuana, Tijuana, Baja California, Mexico
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Conditions
- HER2-positive Breast CancerAdvanced Solid TumorHead and Neck Squamous Cell CarcinomaMetastatic CancerHER2-positive Gastric CancerHER-2 Protein OverexpressionEndometrium CancerCervical CancerEsophageal CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- NKGen Biotech, Inc.
- Registration Number
- NCT04464967
- Prev
- 1
- 2
- Next